Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients

Experimental and Therapeutic Medicine

Volumn 1, Issue 2, 2010, Pages 357-361

  Balogh, Gabriela A ^a   Mailo, Daniel ^a   Nardi, Hector ^a   Corte, Maria Marta ^a   Vincent, Esteban ^a   Barutta, Elena ^a   Lizarraga, Guillermo ^a   Lizarraga, Pablo ^a   Montero, Hector ^a   Gentili, Roberto ^a  

^a National University of the South   (Argentina)

Author keywords

Breast cancer; P53 mutational analysis; Serological detection of p53 mutations

Indexed keywords

PROTEIN P53;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SEROLOGY; TUMOR DIFFERENTIATION;

EID: 77956203602     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm_00000056     Document Type: Article

References (27)

1. Ries L, Eisner M, Kosary C, et al (eds): SEER. In: Cancer Statistics Review. National Cancer Institute, Bethesda, MD, pp 1973-1999, 2002.
2. Greenie RT, Murray T, Boldin S and Wingo P: Cancer statistics 2000. Cancer J Clin 50: 7-23, 2000.
3. Stewart BW and Kleihues P (eds): World Cancer Report. IARC Press, France, 2003.
4. Oliveira AM, Ross JS and Fletcher JA: Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Am J Clin Pathol 124: S16-S28, 2005.
5. Bourdon JC, Laurenzi VD, Melino G and Lane D: p53: 25 years of research and more questions to answer. Cell Death Differ 10: 397-399, 2003.
6. Bourdon JC: P53 and its isoforms in cancer. Br J Cancer 97: 277-282, 2007.
7. Soussi T: The p53 pathway and human cancer. Br J Surg 92: 1331-1332, 2005.
8. Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, Karlan B and Slamon DJ: DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 13: 1971-1981, 1997.
9. Dowell SP, Wilson PO, Derias NW, Lane DP and Hall PA: Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res 54: 2914-2918, 1994.
10. Crawford LV, Pim DC and Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30: 403-408, 1982.
11. Soussi T: Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60: 1777-1788, 2000.
12. Vogl FD, Frey M, Kreienberg R and Runnebaum IB: Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass. Br J Cancer 83: 1338-1343, 2000.
13. Balogh GA, Corte MM, Nardi H, et al: Mutant p53 protein in serum could be used as a molecular marker in human breast cancer. Int J Oncol 8: 995-1002, 2006.
14. Lagios MD: Pathologic practice standards for breast carcinoma: tumor size, reliable data, or miscues? J Am Coll Surg 196: 91-92, 2003.
15. Silverstein MJ and Lagios MD: Pathologic findings from the National Surgical Adjuvant Breast Project (NSA BP) eight-year update of Protocol B-17. Cancer 88: 242-244, 2000.
16. Soussi T: P53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60: 1777-1788, 2000.
17. Crawford LV, Pimand DC and Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30: 403-408, 1982.
18. Choi JH, Oh JY, Ryu SK, et al: Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients. Cancer 79: 1879-1883, 1997.
19. Oh MJ, Choi JH, Kim IH, et al: Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma. Clin Cancer Res 6: 4760-4763, 2000.
20. Sobti RC, Parashar K, Kaurand R and Capalash N: Detection of human papillomavirus DNA, serum p53 and p53 antibodies in patients with cervical cancer. J Environ Pathol Toxicol Oncol 21: 79-85, 2002.
21. Oh MJ, Choi JH, Lee YH, Lee JK, Hur JY, Park YK, Lee KW, Chough SY and Saw HS: Mutant p53 protein in the serum of patients with cervical carcinoma: correlation with the level of serum epidermal growth factor receptor and prognostic significance. Cancer Lett 203: 107-112, 2004.
22. Micelli G, Donadeo A and Quaranta M: The p53 tumor suppressor gene. A preliminary clinical study in breast cancer patients. Cell Biophys 21: 25-31, 1992.
23. Al-Moundhri M, Nirmala V, Al-Mawaly K, Ganguly S, Burney I, Rizvi A and Grant C: Significance of p53, Bcl-2 and HER-2/neu protein expression in Omani Arab females with breast cancer. Pathol Oncol Res 9: 226-231, 2003.
24. Labrecque S, Naor N, Thomson D and Matlashewski G: Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 53: 3468-3471, 1993.
25. Trivers GE, Cawley HL, De Benedetti VM, Hollstein M, Marion MJ, Bennett WP, Hoover ML, Prives CC, Tamburro CC and Harris CC: Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst 87: 1400-1407, 1995.
26. Gormally E, Vineis P, Matullo G, et al: TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res 66: 6871-6876, 2006.
27. Mocci F and Nettuno M: Plasma mutant-p53 protein and anti-p53 antibody as a marker: an experience in vinyl chloride workers in Italy. J Occup Environ Med 48: 158-164, 2006.